Skip to main content
SpringerLink
Log in

Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The objective of this study was to assess the clinical efficacy of genetically engineered recombinant human adenovirus type 5 (rhAd5) plus transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma (HCC). Data from two groups of patients with unresectable HCC were retrospectively reviewed. One group included 149 patients treated with rhAd5 injection, and the other included 150 control patients without gene therapy. Differences in short-term treatment effectiveness and adverse events were recorded and compared between the two groups. Our results indicated that for patients with higher tumor staging in the treatment group, the overall response rate and the disease control rate were higher than those in the control group, but not statistically significant (P > 0.05). The total progression free survival (PFS) and overall survival (OS) were significantly longer in the treatment group than the control group (240 vs. 196 days, P < 0.05; and 1,526 vs. 1,236 days, P = 0.000; respectively). The overall incidence rate of treatment-related adverse effects was similar (P > 0.05). No serious complications were observed. In conclusion, this study suggests that rhAd5 is a safe, effective gene therapy that prolongs the PFS and OS time of patients with unresectable HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase [Internet]. 2014;11.

  2. Tsuchiya M, Watanabe M, Koike J, Kubota Y, Suzuki T, Otsuka Y, et al. Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Gan to kagaku ryoho Cancer & chemotherapy. 2010;37(12):2594–7.

    Google Scholar 

  3. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38. doi:10.1016/j.jhep.2006.05.013.

    Article  PubMed  Google Scholar 

  4. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698–711. doi:10.1093/jnci/djn134.

    Article  PubMed  Google Scholar 

  5. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37(3):212–20. doi:10.1016/j.ctrv.2010.07.006.

    Article  PubMed  Google Scholar 

  6. Li L, Liu RY, Huang JL, Liu QC, Li Y, Wu PH, et al. Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma. Int J Cancer. 2006;118(8):2064–71. doi:10.1002/ijc.21585.

    Article  CAS  PubMed  Google Scholar 

  7. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38(1):37–51. doi:10.1111/j.1872-034X.2007.00216.x.

    Article  PubMed  Google Scholar 

  8. Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993;67(4):773–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17(7):1721–4. doi:10.1245/s10434-010-1024-1.

    Article  PubMed  Google Scholar 

  10. Lencioni R. New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma. Clin Cancer Res. 2013;19(6):1312–4. doi:10.1158/1078-0432.CCR-12-3796.

    Article  PubMed  Google Scholar 

  11. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81. doi:10.1016/S1053-4296(03)00031-6.

    Article  PubMed  Google Scholar 

  12. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  13. Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu FM, et al. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother. 2013;36(5):287–93. doi:10.1097/CJI.0b013e3182948452.

    Article  PubMed  Google Scholar 

  14. Miller DL, Myers CL, Rickards B, Coller HA, Flint SJ. Adenovirus type 5 exerts genome-wide control over cellular programs governing proliferation, quiescence, and survival. Genome Biol. 2007;8(4):R58. doi:10.1186/gb-2007-8-4-r58.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Min YW, Lee JH, Gwak GY, Paik YH, Lee JH, Rhee PL, et al. Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching. J Gastroenterol Hepatol. 2014;29(5):1043–8. doi:10.1111/jgh.12504.

    Article  PubMed  Google Scholar 

  16. Kocyigit A, Dicle O, Goktay Y, Astarcioglu I. The effect of using different embolic agents on survival in transarterial chemoembolization of hepatocellular carcinoma: gelfoam versus polyvinyl alcohol. Diagn Interv Radiol. 2014;. doi:10.5152/dir.2014.13462.

    PubMed  Google Scholar 

  17. Maeda N, Osuga K, Higashihara H, Tomoda K, Mikami K, Nakazawa T, et al. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion. Cardiovasc Interven Radiol. 2012;35(1):82–9. doi:10.1007/s00270-010-0086-6.

    Article  Google Scholar 

  18. Graham FL, van der Eb AJ, Heijneker HL. Size and location of the transforming region in human adenovirus type 5 DNA. Nature. 1974;251(5477):687–91.

    Article  CAS  PubMed  Google Scholar 

  19. Steegenga WT, Riteco N, Jochemsen AG, Fallaux FJ, Bos JL. The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene. 1998;16(3):349–57. doi:10.1038/sj.onc.1201540.

    Article  CAS  PubMed  Google Scholar 

  20. Iftode C, Flint SJ. Viral DNA synthesis-dependent titration of a cellular repressor activates transcription of the human adenovirus type 2 IVa2 gene. Proc Natl Acad Sci USA. 2004;101(51):17831–6. doi:10.1073/pnas.0407786101.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

We express our thanks to the research staff at the collaborating centers for their outstanding work and dedication.

Conflict of interest

All authors have reviewed the final version of the manuscript and approve it for publication. This manuscript has not been published in whole or in part nor is it being considered for publication before by myself, any co-author or by others. The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Medical Imaging and Image Guided Therapy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, East Dong Feng Road 651, Guangzhou, 510060, Guangdong, People’s Republic of China

    Jun Dong, Wang Li, Annan Dong, Siyue Mao, Lujun Shen, Sheng Li & Peihong Wu

  2. Department of Medical Statistics and Epidemiology School of Public Health, Sun Yat-sen University, Zhongshan 2nd Road, 74, Guangzhou, 510080, Guangdong, People’s Republic of China

    Xiao Gong

Authors
  1. Jun Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Annan Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Siyue Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lujun Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sheng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiao Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Peihong Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peihong Wu.

Additional information

Jun Dong and Wang Li have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dong, J., Li, W., Dong, A. et al. Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5. Med Oncol 31, 95 (2014). https://doi.org/10.1007/s12032-014-0095-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0095-4

Keywords

Search

Navigation